Functional interplay between MDM2, p63/p73 and mutant p53

Oncogene

Volumn 34, Issue 33, 2015, Pages 4300-4310

  Stindt, M H ^a   Muller, P A J ^a,c   Ludwig, R L ^a   Kehrloesser, S ^b   Dotsch V ^b   Vousden, K H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; CKAP4 PROTEIN, HUMAN; DNA BINDING PROTEIN; MDM2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; DIMERIZATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; WILD TYPE; CELL LINE; GENETICS; HCT116 CELL LINE; METABOLISM; MUTATION; NEOPLASM; PROTEIN DOMAIN; TUMOR CELL LINE;

CELL LINE; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HCT116 CELLS; HEK293 CELLS; HUMANS; MEMBRANE PROTEINS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84939568847     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.359     Document Type: Article

References (64)

1. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science (New York) NY 1991; 253: 49-53.
3. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429.
4. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2: 466-474.
5. Muller PA, Vousden KH. P53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
6. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. P63, a p53 homolog at 3q27-29, encodes multiple products withtransactivating, deathinducing, and dominant-negative activities. Mol Cell 1998; 3: 305-316.
7. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
8. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62: 636-641.
9. Khoury MP, Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2010; 2: a000927.
10. Natan E, Joerger AC. Structure and kinetic stability of the p63 tetramerization domain. J Mol Biol 2012; 415: 503-513.
11. Ethayathulla AS, Tse PW, Monti P, Nguyen S, Inga A, Fronza G et al. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci USA 2012; 109: 6066-6071.
12. Straub WE, Weber TA, Schafer B, Candi E, Durst F, Ou HD et al. The C-terminus of p63 contains multiple regulatory elements with different functions. Cell Death Dis 2010; 1: e5.
13. Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Schafer B, Hannewald J et al. DNA damage in oocytes induces a switch of the quality control factor TAp63alpha from dimer to tetramer. Cell 2011; 144: 566-576.
14. Luh LM, Kehrloesser S, Deutsch GB, Gebel J, Coutandin D, Schafer B et al. Analysis of the oligomeric state and transactivation potential of TAp73alpha. Cell Death Differ 2013; 20: 1008-1016.
15. Coutandin D, Lohr F, Niesen FH, Ikeya T, Weber TA, Schafer B et al. Conformational stability and activity of p73 require a second helix in the tetramerization domain. Cell Death Differ 2009; 16: 1582-1589.
16. Joerger AC, Rajagopalan S, Natan E, Veprintsev DB, Robinson CV, Fersht AR. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci USA 2009; 106: 17705-17710.
17. Di Como CJ, Gaiddon C, Prives C. P73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438-1449.
18. Gaiddon C, Lokshn M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874-1887.
19. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. Physical interaction with human tumor derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817-18826.
20. Strano S, Munarriz E, Rossi M, Cristofanellu B, Shaul Y, Castagnoli L et al. Physical and functional interaction between p53 mutants and difference isoforms of p73. J Biol Chem 2000; 275: 29503-29512.
21. Santini S, Di Agostino S, Coppari E, Bizzarri AR, Blandino G, Cannistraro S. Interaction of mutant p53 with p73: asurface plasmon resonance and atomic force spectroscopy study. Biochim Biophys Acta 2014; 1840: 1958-1964.
22. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87-98.
23. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
24. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a proinvasive secretome. Oncotarget 2011; 2: 1203-1217.
25. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
26. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
27. Momand J, Zambetti GP, George DL, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
28. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
29. Balint E, Bates S, Vousden KH. Mdm2 binds p73a without targeting degradation. Oncogene 1999; 18: 3923-3929.
30. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19: 3257-3266.
31. Dobbelstein M, Wienzek S, Koenig S, Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 1999; 18: 2101-2106.
32. Kadakia M, Slader C, Berberich SJ. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 2001; 20: 321-330.
33. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002; 277: 2674-2681.
34. Little NA, Jochemsen AG. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 2001; 20: 4576-4580.
35. Kojima T, Ikawa Y, Katoh I. Analysis of molecular interactions of the p53-family p51 (p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors. Biochem Biophys Res Commun 2001; 281: 1170-1175.
36. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007; 26: 2226-2242.
37. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002; 22: 8601-8611.
38. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-295.
39. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-1602.
40. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53 and cancerassociated mutants. Adv Cancer Res 2007; 97: 1-23.
41. Trinidad AG, Muller PA, Cuellar J, Klejnot M, Nobis M, Valpuesta JM et al. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell 2013; 50: 805-817.
42. Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K et al. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 2001; 490: 202-208.
43. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 2011; 9: 577-588.
44. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008; 27: 3371-3383.
45. Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One 2012; 7: e51426.
46. Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, Braga CA et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem 2012; 287: 28152-28162.
47. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
48. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990; 62: 671-680.
49. Midgley CA, Lane DP. P53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179-1189.
50. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-1344.
51. Zheng T, Wang J, Zhao Y, Zhang C, Lin M, Wang X et al. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat Commun 2013; 4: 2996.
52. Zdzalik M, Pustelny K, Kedracka-Krok S, Huben K, Pecak A, Wladyka B et al. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle (Georgetown, TX 2010; 9: 4584-4591.
53. Dotsch V, Bernassola F, Coutandin D, Candi E, Melino G. P63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2010; 2: a004887.
54. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni M, Falco M, Annicchiarico-Petruzzelli M et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188: 1763-1768.
55. Petitjean A, Ruptier C, Tribollet V, Hautefeuille A, Chardon F, Cavard C et al. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 2008; 29: 273-281.
56. De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A et al. P63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 2000; 273: 342-346.
57. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A et al. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differen 2006; 13: 1037-1047.
58. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007; 27: 8284-8295.
59. Chen JD, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-4114.
60. Kubbutat MHG, Ludwig RL, Levine AJ, Vousden KH. Analysis of the degradation function of Mdm2. Cell Growth Differ 1999; 10: 87-92.
61. Osada M, Nagakawa Y, Park HL, Yamashita K, Wu G, Kim MS et al. P63-specific activation of the BPAG-1e promoter. J Invest Dermatol 2005; 125: 52-60.
62. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parson VE, Trent JM et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
63. Stindt MH, Carter S, Vigneron AM, Ryan KM, Vousden KH. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle (Georgetown, TX) 2011; 10: 3176-3188.
64. Collins TJ. Image J for microscopy. Biotechniques 2007; 43: 25-30.